Skip to main content
SpringerLink
Log in

Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal del Castillo T, al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 126(3):291–299

    Article  PubMed  PubMed Central  Google Scholar 

  2. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G (2010) Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107(16):7473–7478

    Article  PubMed  PubMed Central  Google Scholar 

  3. Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ (2016) TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023–2036

    Article  PubMed  PubMed Central  Google Scholar 

  4. Spencer DH, Russler-Germain DA, Ketkar S, Helton NM, Lamprecht TL, Fulton RS, Fronick CC, O’Laughlin M, Heath SE, Shinawi M, Westervelt P, Payton JE, Wartman LD, Welch JS, Wilson RK, Walter MJ, Link DC, DiPersio JF, Ley TJ (2017) CpG Island hypermethylation mediated by DNMT3A is a consequence of AML progression. Cell 168(5):801–816.e13

    Article  PubMed  PubMed Central  Google Scholar 

  5. Glass JL, Hassane D, Wouters BJ, Kunimoto H, Avellino R, Garrett-Bakelman FE, Guryanova OA, Bowman R, Redlich S, Intlekofer AM, Meydan C, Qin T, Fall M, Alonso A, Guzman ML, Valk PJM, Thompson CB, Levine R, Elemento O, Delwel R, Melnick A, Figueroa ME (2017) Epigenetic identity in AML depends on disruption of nonpromoter regulatory elements and is affected by antagonistic effects of mutations in epigenetic modifiers. Cancer Discov 7(8):868–883

    Article  PubMed  PubMed Central  Google Scholar 

  6. Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF (2010) Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 28(4):556–561

    Article  PubMed  Google Scholar 

  7. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670–2677

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lübbert M, Rüter BH, Claus R, Schmoor C, Schmid M, Germing U et al (2012) A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 97(3):393–401

    Article  PubMed  PubMed Central  Google Scholar 

  9. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447

    Article  PubMed  PubMed Central  Google Scholar 

  10. Huang J, Zhao H, Hong M, Zhu H, Zhu Y, Lian Y, Li S, Li J, Qian S (2018) Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia. BMC Cancer 18(1):1269

    Article  PubMed  PubMed Central  Google Scholar 

  11. Gang AO, Frøsig TM, Brimnes MK, Lyngaa R, Treppendahl MB, Grønbæk K, Dufva IH, Straten P, Hadrup SR (2014) 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J 4(3):e197

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lindblad KE, Goswami M, Hourigan CS, Oetjen KA (2017) Immunological effects of hypomethylating agents. Expert Rev Hematol 10(8):745–752

    Article  PubMed  PubMed Central  Google Scholar 

  13. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 133(1):7–17

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, Minneapolis, MN, 55455, USA

    Joseph E. Maakaron

  2. The Ohio State University, Columbus, OH, USA

    Michael P. Ozga & Alice S. Mims

  3. Stanford School of Medicine, Stanford, CA, USA

    Gabriel N. Mannis

  4. University of North Carolina, Chapel Hill, NC, USA

    Will Pulley, Matthew C. Foster & Joshua F. Zeidner

Authors
  1. Joseph E. Maakaron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Ozga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gabriel N. Mannis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Will Pulley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew C. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joshua F. Zeidner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alice S. Mims
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph E. Maakaron.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Novelty

This is the first report to describe prolonged and sustained remissions in patients with acute myeloid leukemia after limited-duration therapy with hypomethylating agents. We attempt to characterize patients who have achieved long-term remissions with hypomethylating agents in this report.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maakaron, J.E., Ozga, M.P., Mannis, G.N. et al. Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia. Ann Hematol 99, 1411–1413 (2020). https://doi.org/10.1007/s00277-020-04054-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-04054-x

Search

Navigation